
VistaGen Therapeutics VTGN
$ 0.16
-15.79%
VistaGen Therapeutics Total Assets | VTGN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.6 M | 84.3 M | 124 M | 21.1 M | 74.6 M | 108 M | 5.77 M | 14 M | 11.3 M | 3.71 M | 990 K | 270 K | 264 K | 882 K | 342 K | 324 K | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 264 K | 31.2 M |
Quarterly Total Assets VistaGen Therapeutics
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.4 M | 35.7 M | 48.6 M | 65.1 M | 80.9 M | 68.9 M | 84.3 M | 92.3 M | 102 M | 114 M | 124 M | 131 M | 42.2 M | 15 M | 21.1 M | 42.2 M | 15 M | 21.1 M | 74.6 M | 29.7 M | 58.7 M | 58.7 M | 90.5 M | 100 M | 104 M | 104 M | 109 M | 20.3 M | 6.17 M | 12.9 M | 5.33 M | 8.74 M | 12.9 M | 14 M | 11.3 M | 14.2 M | 8.26 M | 2.44 M | 3.71 M | 2.62 M | 2.44 M | 3.71 M | 990 K | 7.02 M | 7.02 M | 8.76 M | 270 K | 1.93 M | 1.74 M | 270 K | 264 K | 387 K | 765 K | 765 K | 329 K | 329 K | 406 K | 432 K | 264 K | 425 K | 645 K | 645 K | 882 K | 537 K | 1.68 M | 1.68 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | 264 K | 30.7 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Johnson & Johnson
JNJ
|
199 B | $ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
42.2 M | $ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
359 M | $ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
148 M | $ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
379 M | $ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
157 M | $ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
258 M | $ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
76.9 M | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
583 M | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
325 M | $ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
113 M | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
13.5 M | $ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
112 B | $ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
1.66 B | $ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
20 M | $ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
168 M | $ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
82.8 M | $ 76.99 | 0.03 % | $ 997 M | ||
|
Curis
CRIS
|
20 M | $ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
826 M | $ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
146 M | $ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
27 M | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
785 M | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
843 M | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
792 M | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
9.95 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
137 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
12.3 B | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
29.8 M | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
111 B | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
216 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
324 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
30.5 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
571 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
341 M | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
259 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
45.8 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
172 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
21.4 B | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
328 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
61.1 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
45.6 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
2.9 B | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
4.5 M | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
55.2 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
683 M | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
10.1 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
6.96 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
32.4 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
493 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
40.6 B | $ 920.38 | -0.22 % | $ 96.3 B |